BACKGROUND: Pure red cell aplasia and moderate aplastic anemia are marrow failure states with an immune pathogenesis. Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and pure red cell aplasia (PRCA) patients with daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor; we now report our long-term experience with a larger cohort of patients. DESIGN AND METHODS: After a median follow-up period of 4.8 years, 19 of 45 (42%) evaluable mAA patients and 10 of 26 (38%) patients with PRCA responded by three months and 2 additional mAA patients responded by six months following administration of the drug. RESULTS: Seven of 28 (25%) mAA patients achieved long-term packed red blood cell PRBC transfusion independence, and all PRCA responders achieved long-term transfusion PRBC transfusion independence. CONCLUSIONS: Red cell transfusion-independence prior to treatment in mAA patients predicted response. The only significant adverse treatment-related events were transient rashes and arthralgias. Daclizumab is safe and effective, and produces lengthy remissions in patients with PRCA and mAA.
BACKGROUND: Pure red cell aplasia and moderate aplastic anemia are marrow failure states with an immune pathogenesis. Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and pure red cell aplasia (PRCA) patients with daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor; we now report our long-term experience with a larger cohort of patients. DESIGN AND METHODS: After a median follow-up period of 4.8 years, 19 of 45 (42%) evaluable mAA patients and 10 of 26 (38%) patients with PRCA responded by three months and 2 additional mAA patients responded by six months following administration of the drug. RESULTS: Seven of 28 (25%) mAA patients achieved long-term packed red blood cell PRBC transfusion independence, and all PRCA responders achieved long-term transfusion PRBC transfusion independence. CONCLUSIONS: Red cell transfusion-independence prior to treatment in mAA patients predicted response. The only significant adverse treatment-related events were transient rashes and arthralgias. Daclizumab is safe and effective, and produces lengthy remissions in patients with PRCA and mAA.
Authors: G L Bumgardner; I Hardie; R W Johnson; A Lin; B Nashan; M D Pescovitz; E Ramos; F Vincenti Journal: Transplantation Date: 2001-09-15 Impact factor: 4.939
Authors: D Przepiorka; N A Kernan; C Ippoliti; E B Papadopoulos; S Giralt; I Khouri; J G Lu; J Gajewski; A Durett; K Cleary; R Champlin; B S Andersson; S Light Journal: Blood Date: 2000-01-01 Impact factor: 22.113
Authors: Steven Yeh; Keith Wroblewski; Ronald Buggage; Zhuqing Li; Shree K Kurup; Hatice Nida Sen; Sam Dahr; Pushpa Sran; George F Reed; Randy Robinson; Jack A Ragheb; Thomas A Waldmann; Robert B Nussenblatt Journal: J Autoimmun Date: 2008-06-20 Impact factor: 7.094
Authors: Jean Tkaczuk; Chao-Lan Yu; Shairaz Baksh; Edgar L Milford; Charles B Carpenter; Steven J Burakoff; Dianne B McKay Journal: Am J Transplant Date: 2002-01 Impact factor: 8.086
Authors: G Vlad; E K Ho; E R Vasilescu; J Fan; Z Liu; J W Cai; Z Jin; E Burke; M Deng; M Cadeiras; R Cortesini; S Itescu; C Marboe; D Mancini; N Suciu-Foca Journal: Transpl Immunol Date: 2007-04-02 Impact factor: 1.708
Authors: Bhumika J Patel; Shimoli V Barot; Teodora Kuzmanovic; Cassandra Kerr; Bartlomiej P Przychodzen; Swapna Thota; Sarah Lee; Saurabh Patel; Tomas Radivoyevitch; Alan Lichtin; Anjali Advani; Matt Kalaycio; Mikkael A Sekeres; Hetty E Carraway; Jaroslaw P Maciejewski Journal: Br J Haematol Date: 2020-01-31 Impact factor: 8.615